4-(methylsulfonyl)benzhydroximic acid chloride | 572913-23-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(methylsulfonyl)benzhydroximic acid chloride
• 英文别名: 4-methanesulfonylbenzoylchloride oxime；N-hydroxy-4-(methylsulfonyl)benzimidoyl chloride；N-hydroxy-4-methylsulfonylbenzenecarboximidoyl chloride
• CAS: 572913-23-6
• 化学式: C₈H₈ClNO₃S
• 分子量: 233.675
• InChiKey: JUGUQJCEBPLPKZ-UHFFFAOYSA-N

物化性质

• 熔点：
  183-185 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  447.2±51.0 °C(Predicted)
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  75.1
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(benzo[d][1,3]dioxol-5-yl)ethyne-1-sulfonyl fluoride 、 4-(methylsulfonyl)benzhydroximic acid chloride 在 三乙胺 作用下， 以 甲苯 为溶剂， 反应 0.17h， 以91%的产率得到5-(benzo[d][1,3]dioxol-5-yl)-3-(4-(methylsulfonyl)phenyl)isoxazole-4-sulfonyl fluoride
  参考文献：
  名称：

  多样性定向点击 (DOC)：从 2-取代-炔基-1-磺酰氟 (SASF) 枢纽合成 SuFExable 药效团的发散合成。

  摘要：

  面向多样性的点击 (DOC) 是一种统一的点击方法，用于通过应用广泛的点击转换家族来模块化合成类先导结构。DOC 从实现“轻松实现多样性”的概念演变而来，将经典的 C−C π 键点击化学与连接性 SuFEx 技术的最新发展相结合。我们展示了 2-取代的- A炔基-1-磺酰基F氟化物（SASFs）作为一类新的连接枢纽，与多种点击环加成过程相结合。通过具有一系列偶极子和环状二烯的 SASF 的选择性 DOC，我们以最少的合成步骤报告了 173 种独特功能分子的多样化点击库。SuFExable 库包含 10 个离散的杂环核心结构，这些核心结构源自 1,3- 和 1,5- 偶极子；而与环状二烯的反应会产生几种三维双环 Diels-Alder 加合物。通过对 96 孔板中的磺酰氟侧基进行 SuFEx 点击衍生化，可以通过后期修饰将文库增加到 278 种离散化合物——证明了 DOC 方法在快速合成不同功能结构方面的多功能性。

  DOI：

  10.1002/anie.202003219
• 作为产物：
  描述：

  4-(甲基磺酰基)苯甲醛肟 在 N-氯代丁二酰亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 生成 4-(methylsulfonyl)benzhydroximic acid chloride
  参考文献：
  名称：

  多样性定向点击 (DOC)：从 2-取代-炔基-1-磺酰氟 (SASF) 枢纽合成 SuFExable 药效团的发散合成。

  摘要：

  面向多样性的点击 (DOC) 是一种统一的点击方法，用于通过应用广泛的点击转换家族来模块化合成类先导结构。DOC 从实现“轻松实现多样性”的概念演变而来，将经典的 C−C π 键点击化学与连接性 SuFEx 技术的最新发展相结合。我们展示了 2-取代的- A炔基-1-磺酰基F氟化物（SASFs）作为一类新的连接枢纽，与多种点击环加成过程相结合。通过具有一系列偶极子和环状二烯的 SASF 的选择性 DOC，我们以最少的合成步骤报告了 173 种独特功能分子的多样化点击库。SuFExable 库包含 10 个离散的杂环核心结构，这些核心结构源自 1,3- 和 1,5- 偶极子；而与环状二烯的反应会产生几种三维双环 Diels-Alder 加合物。通过对 96 孔板中的磺酰氟侧基进行 SuFEx 点击衍生化，可以通过后期修饰将文库增加到 278 种离散化合物——证明了 DOC 方法在快速合成不同功能结构方面的多功能性。

  DOI：

  10.1002/anie.202003219

文献信息

• Design, synthesis, and in vitro evaluation of novel antifungal triazoles
  作者：Fei Xie、Tingjunhong Ni、Jing Zhao、Lei Pang、Ran Li、Zhan Cai、Zichao Ding、Ting Wang、Shichong Yu、Yongsheng Jin、Dazhi Zhang、Yuanying Jiang

  DOI：10.1016/j.bmcl.2017.03.062

  日期：2017.5

  Twenty-nine novel triazole analogues of ravuconazole and isavuconazole were designed and synthesized. Most of the compounds exhibited potent in vitro antifungal activities against 8 fungal isolates. Especially, compounds a10, a13, and a14 exhibited superior or comparable antifungal activity to ravuconazole against all the tested fungi. Structure-activity relationship study indicated that replacing

  设计并合成了二十一种新颖的拉伏康唑和伊沙康康唑的三唑类似物。大多数化合物对8种真菌分离物均表现出有效的体外抗真菌活性。尤其是，化合物a10，a13和a14对所有测试的真菌均表现出比ravuconazole更高或相当的抗真菌活性。构效关系研究表明，用氟代苯基异恶唑取代氟康唑的4-氰基苯基硫唑部分，可得到更有效，更广谱的新型抗真菌三唑。
• 一种三氮唑醇类衍生物及其制备方法和应用
  申请人：中国人民解放军第二军医大学

  公开号：CN106336383B

  公开（公告）日：2019-05-14

  本发明涉及一种三氮唑醇类衍生物及其制备方法和应用，所述的三氮唑醇类衍生物的化学结构如式I所示。本发明还提供了所述化合物的盐类、药物组合物、制备方法和用途。本发明的化合物具有较强的抗真菌活性，且具有毒性低、抗菌谱广等优点，可用于制备抗真菌药物。
• 1-Bromoethene-1-sulfonyl fluoride (1-Br-ESF), a new SuFEx clickable reagent, and its application for regioselective construction of 5-sulfonylfluoro isoxazoles
  作者：Jing Leng、Hua-Li Qin

  DOI：10.1039/c8cc00986d

  日期：——

  A new fluorosulfonylation reagent 1-bromoethene-1-sulfonyl fluoride was developed (1-Br-ESF). This unique reagent possesses three addressable handles (vinyl, bromide, and sulfonyl fluoride) and has great potential to function as a tris-electrophile and as a sulfur(VI) fluoride exchange (SuFEx) clickable material to enrich the SuFEx tool cabinet. The application of this reagent for regioselective synthesis

  开发了一种新的氟磺酰化试剂1-溴乙烯-1-磺酰氟（1-Br-ESF）。这种独特的试剂具有三个可寻址的手柄（乙烯基，溴化物和磺酰氟），并且具有巨大的潜力，可以用作三亲电子试剂和硫（VI）氟化物交换（SuFEx）可点击材料，以丰富SuFEx工具柜。通过与N-羟基苯甲酰亚胺基氯进行[3 + 2]环加成反应，已经实现了该试剂在5-磺酰基氟异恶唑的区域选择性合成中的应用。该实用方案提供了具有磺酰氟部分的官能化异恶唑的一般直接途径。
• Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability
  作者：Maria Laura Pati、Paola Vitale、Savina Ferorelli、Mariaclara Iaselli、Morena Miciaccia、Angelina Boccarelli、Giuseppe Davide Di Mauro、Cosimo G. Fortuna、Thaisa Francielle Souza Domingos、Luiz Cláudio Rodrigues Pereira da Silva、Marcelo de Pádula、Lucio Mendes Cabral、Plínio Cunha Sathler、Angelo Vacca、Antonio Scilimati、Maria Grazia Perrone

  DOI：10.1016/j.ejmech.2018.12.029

  日期：2019.2

  A set of novel diarylisoxazoles has been projected using mofezolac (1) as a lead compound to investigate structure-inhibitory activity relationships of new compounds and the cyclooxygenases (COXs) catalytic activity. Mofezolac was chosen because is the most potent and selective reversible COX-1 inhibitor [COX-1 IC50 = 0.0079 mu M and COX-2 IC50 > 50 mu M, with a selectivity index (SI) in favor of COX-1 higher than 6300]. Seventeen new compounds were synthesized in fair to good yields and evaluated for their COXs inhibitory activity and selectivity. Sls ranged between 1 and higher than 11903,4-Bis(4-methoxyphenyl)-5-vinylisoxazole (22) has the highest SI with COX-1 IC50 = 0.042 mu M and COX-2 IC50 > 50 mu M. 1 and 22 were superior to aspirin in inhibiting platelet aggregation (IC50 = 0.45, 0.63 and 1.11 mu M, respectively) in human platelet rich plasma (hPRP) assay. They did not induce blood coagulation and hemolysis, and are neither genotoxic nor mutagen. 1 and 22 slightly increase bortezomib cytotoxic effect on multiple myeloma (MM) cell lines (NCI-H929 and RPMI-8226) and affects MM cell cycle and apoptosis when co-administered with the proteasome inhibitor bortezomib, a drug clinically used to treat plasma cell neoplasms including MM. In addition, structure-based binding mode of 1 and 22, through Fingerprints for Ligands and Proteins (FLAG) calculation, allowed to explain the one order of magnitude difference between COX-1 IC50 values of the two compounds. Specifically, the higher inhibitory potency seems due to the formation of a H-bond between COX-1 S530 and the carboxyl, present in 1 and absent in 22. (C) 2018 Elsevier Masson SAS. All rights reserved.
• Synthesis of heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors: effects on the inhibitory activity of the replacement of the cyclopentene central core with pyrazole, thiophene or isoxazole ring
  作者：Aldo Balsamo、Isabella Coletta、Angelo Guglielmotti、Carla Landolfi、Francesca Mancini、Adriano Martinelli、Claudio Milanese、Filippo Minutolo、Susanna Nencetti、Elisabetta Orlandini、Mario Pinza、Simona Rapposelli、Armando Rossello

  DOI：10.1016/s0223-5234(02)01448-4

  日期：2003.2

  Several heteroaromatic analogues of (2-aryl-1-cyclopentenyl-1-alkylidene)-(arylmethyloxy)amine COX-2 inhibitors, in which the cyclopentene moiety was replaced by pyrazole, thiophene or isoxazole ring, were synthesized, in order to verify the influence of the different nature of the central core on the COX inhibitory properties of these kinds of molecules. Among the compounds tested, only the 3-(p-methylsulfonylphenyl) substituted thiophene derivatives 17 and 22, showed a certain COX-2 inhibitory activity, accompanied by an appreciable COX-2 versus COX-1 selectivity. Only one of the 1-(p-methylsulfonylphenyl)pyrazole compounds (16) displayed a modest inhibitory activity towards both type of isoenzymes. while the pyrazole 1-(p-aminosulfonylphenyl) substituted 12 proved to be significantly active only towards COX-1. All the isoxazole derivatives were inactive on both COX isoforms. (C) 2003 Editions scientifiques et medicales Elsevier SAS. All rights reserved.